NCT06106945 - AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

226

Participants

Timeline

Start Date

December 5, 2023

Primary Completion Date

March 15, 2027

Study Completion Date

March 15, 2027

Conditions

Multiple Myeloma

Interventions

DRUG

AZD0305

Trial Locations (33)

3000

RECRUITING

Research Site, Melbourne

6009

RECRUITING

Research Site, Nedlands

10065

RECRUITING

Research Site, New York

19104

RECRUITING

Research Site, Philadelphia

20246

RECRUITING

Research Site, Hamburg

22031

RECRUITING

Research Site, Fairfax

23538

RECRUITING

Research Site, Lübeck

28027

RECRUITING

Research Site, Madrid

28041

RECRUITING

Research Site, Madrid

30322

RECRUITING

Research Site, Atlanta

31005

RECRUITING

Research Site, Pamplona

37007

RECRUITING

Research Site, Salamanca

44000

RECRUITING

Research Site, Nantes

45147

RECRUITING

Research Site, Essen

48109

RECRUITING

Research Site, Ann Arbor

59037

RECRUITING

Research Site, Lille

63110

RECRUITING

Research Site, St Louis

79106

WITHDRAWN

Research Site, Freiburg im Breisgau

90419

RECRUITING

Research Site, Nuremberg

91010

RECRUITING

Research Site, Duarte

92618

RECRUITING

Research Site, Irvine

97080

RECRUITING

Research Site, Würzburg

100044

RECRUITING

Research Site, Beijing

110134

RECRUITING

Research Site, Shenyang

410013

RECRUITING

Research Site, Changsha

510060

RECRUITING

Research Site, Guangzhou

02215

RECRUITING

Research Site, Boston

L8V 5C2

RECRUITING

Research Site, Hamilton

K1H 8L6

RECRUITING

Research Site, Ottawa

H4A 3J1

RECRUITING

Research Site, Montreal

277-8577

RECRUITING

Research Site, Kashiwa

467-8602

RECRUITING

Research Site, Nagoya

990-9585

RECRUITING

Research Site, Yamagata